Loading
Life sciences · Journal article
Scientific Reports · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in obesity and can progress to steatohepatitis (MASH), fibrosis, cirrhosis and liver failure. The intestinal microbiome (IM) and metabolites may play a role in MASLD severity but their potential relationships with the hepatic transcriptome are not clear. We investigated these relationships in 93 patients undergoing bariatric surgery who provided blood and fecal samples prior to surgery for biochemical, metabolite (serum, fecal) and IM (metagenomics) measurements. A liver biopsy was obtained to assess histology and the hepatic transcriptome. Patients with MASH had higher expression of genes related to immune system, inflammation, cancer and apoptosis, higher Blautia species and lower Faecalibacterium prausnitzii, Bacteroides dorei, and Coprococcus species. Patients with severe fibrosis had higher expression of extracellular matrix-related genes and higher Collinsella stercoris. Significant associations were identified between differentially expressed genes in the liver, mainly related to growth, proliferation, metabolism and immune system, and bacterial taxa, especially B. dorei and F. prausnitzii, and fecal/serum metabolites (e.g. primary bile acids and acylcarnitines). Our findings demonstrate that fecal bacterial taxa as well as serum and fecal metabolites are associated with hepatic transcriptome according to MASLD severity. However, when adjusted for covariates known to be associated with MASLD definition or severity, these associations did not remain significant. Nonetheless, these interactions may suggest potential pathways and treatment targets requiring further study.